Nuevos retos en la optimización de los dispositivos de resincronización

Cardiac resynchronization therapy has shown benefits in up to 70% of patients with left ventricular dysfunction and left bundle branch block. The availability in the market of devices that are able to produce different atrioventricular or ventricular activation sequences will help optimize device effectiveness and, hence, improve the clinical responses of patients with heart failure. However, much has still to be learned about how they should be programmed, about the best methodology to use, and about their clinical efficacy. Here, we review the extent of current limitations to our knowledge.